A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and Ad26.RSV.preF, With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Influenza virus vaccine (Primary) ; JNJ 64400141 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen Vaccines and Prevention B.V
- 02 Jan 2018 Planned End Date changed from 5 Jul 2018 to 13 Jul 2018.
- 14 Dec 2017 Status changed from not yet recruiting to recruiting.
- 16 Nov 2017 New trial record